Eledon Pharmaceuticals, Inc.
No enriched coverage for $ELDN in the last 7 days.
No SEC Form 4 filings for $ELDN in the last 30 days.
Eledon Pharmaceuticals Inc. (ELDN) has filed an SEC Form DEFA14A. The article also provides recent analyst ratings for ELDN, including targets from H.C. Wainwright, Guggenheim, Cantor Fitzgerald, and HC Wainwright & Co., alongside a list of related SEC filings and press releases concerning the company.
Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus
IRVINE, Calif., Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- Eledon Pharmaceuticals, Inc. ( "Eledon" ) ( NASDAQ:ELDN ) , today announced the pricing of its underwritten public offering of ( i ) 15,152,485 shares of its common stock at a public offering price of $1.65 per share and ( ii ) in lieu of ...
